Skip to main content
Sign In

Flaig Research Lab

Flaig Lab Pic
From left to right: Xiaoping Yang, Thomas Flaig, Lih-Jen Su

Main Research Focus:
Genitourinary Cancer Translational Research

Selected Publications: 

  1. Arthur C, Flaig T, Su L, Denney R, Barnes F, Glodé LM.  The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines.  Ultrasonics.  2007; 46(1): 68-73.  PMID 17173946
  2. Flaig TW, Su Lih-Jen, Agarwal R, Glodé LM.  Silibinin synergizes with mitoxantrone to inhibit cell growth via apoptosis in prostate cancer cells.  International Journal of Cancer.  2007; 120(9): 2028-33.  PMID  17230508
  3. Flaig TW, Su L, Uhlik C, Li Y, Raben D, Garcia M, and Bemis L Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.  BJU International. 2009; 103(12): 1729-37.  PMID 19220256
  4. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su L, Yuan L, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M.  A Study of High-Dose Oral Silybin-Phytosome Followed by Prostatectomy in Patients with Localized Prostate Cancer.  The Prostate. 2010; 70(8): 848-55.  PMID 20127732
  5. Li Y, Yang X, Su L, Flaig TW.  VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cells.  Oncology Reports. 2010; 24(4): 1019-28. PMID: 20811684
  6. Li Y, Yang X, Su L, Flaig, TW.  Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.  Urology. 2011;78(1): 233.e7—233.e13.  PMID 21529900  PMC3126899
  7. Yang X, Bemis L, Su L-J, Gao D, Flaig TW.  miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.  BioResearch Open Access. 2012, 1(2): 55-62.   PMID:23514806
  8. Yang X, Kessler E, Su, L Thorburn A, Frankel AE, Li Y,  La Rosa FG, Shen J, Li C, Varella-Garcia M, Glodé LM, Flaig TW.  Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer.  Clinical Cancer Research. 2012; 19(1): 148-57.  PMID:23172881


University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.